Proposed Changes to Best Price and Market Dynamics

This technical report discusses the proposed rule titled 'Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program (MDRP)' by CMS, which aims to amend the definition of Best Price. The proposed change requires manufacturers to aggregate all price concessions throughout the supply chain for a single unit of a drug, potentially increasing Medicaid rebate liability for certain drugs. The analysis evaluates the implications of this policy change across three drug classes: antipsychotics, multiple sclerosis, and oncology. It estimates that the statutory basic rebate for affected drugs could increase by 17%-21%. The report also outlines potential market responses, including adjustments in commercial payer rebates, restructuring of supply chain discounts, and changes in dynamics between manufacturers and state Medicaid programs. The report highlights the evolving Medicaid drug pricing landscape and anticipates that upcoming CMS decisions will further shape market impacts.